XZB-0004 is under clinical development by SignalChem Lifesciences and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect XZB-0004’s likelihood of approval (LoA) and phase transition for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) took place on 08 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 08 Aug 2022 decreased XZB-0004’s LoA and PTSR for Non-Small Cell Lung Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their XZB-0004 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

XZB-0004 overview

SLC-391 is under development for the treatment of solid tumors, non-small cell lung cancer (NSCLC), acute myelocytic leukemia (AML), colorectal cancer, coronavirus disease (COVID-19) and unspecified hematological malignancies. The drug candidate is a small molecule that acts by targeting AXL kinase. It is developed based on the KineCore technology. It is administered through oral route. The drug candidate was also under development for colon carcinoma and ovarian cancer.  SLC-391 was under development for the treatment of chronic myelocytic leukemia (CML), ovarian cancer, colon carcinoma.

SignalChem Lifesciences overview

SignalChem Lifesciences (SLC) is a biotechnology company that discovers and develops novel therapies for oncology. The company is investigating SLC-391, an orally bioavailable small molecule AXL inhibitors to treat acute myelogenous leukemia and non-small cell lung cancer; and SLC-0111, a carbonic anhydrase IX (CAIX) Inhibitor targeting pancreatic cancer. It is also evaluating additional programs targeting cancer and SARS-CoV-2 (corona virus). SLC provides drug discovery, in-vitro diagnostic development, research and development solutions. The company works in collaboration with pharmaceutical and biopharmaceutical companies to develop its products. SLC is headquartered in Richmond, British Columbia, Canada.

Quick View XZB-0004 LOA Data

Report Segments
  • Innovator
Drug Name
  • XZB-0004
Administration Pathway
  • Oral
Therapeutic Areas
  • Hematological Disorders
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.